Nepafenac structure
|
Common Name | Nepafenac | ||
---|---|---|---|---|
CAS Number | 78281-72-8 | Molecular Weight | 254.284 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 562.5±50.0 °C at 760 mmHg | |
Molecular Formula | C15H14N2O2 | Melting Point | 177-181ºC | |
MSDS | USA | Flash Point | 294.0±30.1 °C | |
Symbol |
GHS09 |
Signal Word | Warning |
Use of NepafenacNepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.IC50 value:Target: COX-2Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery. |
Name | nepafenac |
---|---|
Synonym | More Synonyms |
Description | Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.IC50 value:Target: COX-2Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery. |
---|---|
Related Catalog | |
Target |
COX-1:64.3 μM (IC50) COX-2 |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 562.5±50.0 °C at 760 mmHg |
Melting Point | 177-181ºC |
Molecular Formula | C15H14N2O2 |
Molecular Weight | 254.284 |
Flash Point | 294.0±30.1 °C |
Exact Mass | 254.105530 |
PSA | 86.18000 |
LogP | 0.73 |
Vapour Pressure | 0.0±1.5 mmHg at 25°C |
Index of Refraction | 1.641 |
Storage condition | Refrigerator |
~84% Nepafenac CAS#:78281-72-8 |
Literature: Medichem, S.A. Patent: US2009/312575 A1, 2009 ; Location in patent: Page/Page column 5-6 ; |
~% Nepafenac CAS#:78281-72-8 |
Literature: Journal of Medicinal Chemistry, , vol. 33, # 8 p. 2296 - 2304 |
~% Nepafenac CAS#:78281-72-8 |
Literature: US5475034 A1, ; |
Precursor 2 | |
---|---|
DownStream 0 |
HS Code | 2924299090 |
---|---|
Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections.
Clin. Ophthalmol. 4 , 1249-52, (2010) The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macu... |
Benzeneacetamide, 2-amino-3-benzoyl- |
Nevanac |
2-(2-Amino-3-benzoylphenyl)acetamide |
Nepafenac |
Nepafanac |
2-Amino-3-benzoylbenzeneacetamide |
2-[2-amino-3-(phénylcarbonyl)phényl]acétamide |
AL 6515 |
AHR 9434 |
2-[2-Amino-3-(phenylcarbonyl)phenyl]acetamid |
2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide |
2-Amino-3-benzoyl-phenylacetamide |